Company Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.

The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Savara Inc.

Country	United States
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	70
CEO	Matthew Pauls

Contact Details

Address: The Tannery, Suite 200 Yardley, Pennsylvania 19067 United States
Website	savarapharma.com

Stock Details

Ticker Symbol	SVRA
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001160308
CUSIP Number	805111101
ISIN Number	US8051111016
Employer ID	84-1318182
SIC Code	2834

Key Executives

Name	Position
Matthew Pauls J.D., M.B.A.	Chairman and Chief Executive Officer
David L. Lowrance CPA	Chief Financial and Administrative Officer and Secretary
Robert Matthew Lutz M.B.A.	Chief Operating Officer
Dr. Yasmine Wasfi M.D., Ph.D.	Chief Medical Officer
Kate McCabe J.D.	Chief Legal Officer
Anne Erickson	Chief Business and Corporate Affairs Officer
Brian Maurer	Head of Clinical Operations
Charles LaPree	Executive Vice President and Head of Global Regulatory Affairs
Dr. Brian Robinson M.D.	Executive Vice President of Global Medical Affairs
Dr. Siddharth J. Advant Ph.D.	Executive Vice President of Global Technical Operations

Latest SEC Filings

Date	Type	Title
Jun 22, 2026	144	Filing
Jun 8, 2026	8-K	Current Report
May 12, 2026	10-Q	Quarterly Report
Apr 24, 2026	ARS	Filing
Apr 24, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2026	DEF 14A	Other definitive proxy statements
Apr 10, 2026	PRE 14A	Other preliminary proxy statements
Mar 13, 2026	8-K	Current Report
Mar 13, 2026	10-K	Annual Report
Feb 17, 2026	SCHEDULE 13G/A	Filing

View All SEC Filings